Cargando…

All-Purpose Containers? Lipid-Binding Protein – Drug Interactions

The combined use of in vitro ((19)F-NMR) and in silico (molecular docking) procedures demonstrates the affinity of a number of human calycins (lipid-binding proteins from ileum, liver, heart, adipose tissue and epidermis, and retinol-binding protein from intestine) for different drugs (mainly steroi...

Descripción completa

Detalles Bibliográficos
Autores principales: Beringhelli, Tiziana, Gianazza, Elisabetta, Maggioni, Daniela, Scanu, Sandra, Parravicini, Chiara, Sensi, Cristina, Monaco, Hugo L., Eberini, Ivano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500398/
https://www.ncbi.nlm.nih.gov/pubmed/26167932
http://dx.doi.org/10.1371/journal.pone.0132096
_version_ 1782380903646887936
author Beringhelli, Tiziana
Gianazza, Elisabetta
Maggioni, Daniela
Scanu, Sandra
Parravicini, Chiara
Sensi, Cristina
Monaco, Hugo L.
Eberini, Ivano
author_facet Beringhelli, Tiziana
Gianazza, Elisabetta
Maggioni, Daniela
Scanu, Sandra
Parravicini, Chiara
Sensi, Cristina
Monaco, Hugo L.
Eberini, Ivano
author_sort Beringhelli, Tiziana
collection PubMed
description The combined use of in vitro ((19)F-NMR) and in silico (molecular docking) procedures demonstrates the affinity of a number of human calycins (lipid-binding proteins from ileum, liver, heart, adipose tissue and epidermis, and retinol-binding protein from intestine) for different drugs (mainly steroids and vastatins). Comparative evaluations on the complexes outline some of the features relevant for interaction (non-polar character of the drugs; amino acids and water molecules in the protein calyx most often involved in binding). Dissociation constants (K(i)) for drugs typically lie in the same range as K(i) for natural ligands; in most instances (different proteins and docking conditions), vastatins are the strongest interactors, with atorvastatin ranking top in half of the cases. The affinity of some calycins for some of the vastatins is in the order of magnitude of the drug C(max) after systemic administration in humans. The possible biological implications of this feature are discussed in connection with drug delivery parameters (route of administration, binding to carrier proteins, distribution to, and accumulation in, human tissues).
format Online
Article
Text
id pubmed-4500398
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45003982015-07-17 All-Purpose Containers? Lipid-Binding Protein – Drug Interactions Beringhelli, Tiziana Gianazza, Elisabetta Maggioni, Daniela Scanu, Sandra Parravicini, Chiara Sensi, Cristina Monaco, Hugo L. Eberini, Ivano PLoS One Research Article The combined use of in vitro ((19)F-NMR) and in silico (molecular docking) procedures demonstrates the affinity of a number of human calycins (lipid-binding proteins from ileum, liver, heart, adipose tissue and epidermis, and retinol-binding protein from intestine) for different drugs (mainly steroids and vastatins). Comparative evaluations on the complexes outline some of the features relevant for interaction (non-polar character of the drugs; amino acids and water molecules in the protein calyx most often involved in binding). Dissociation constants (K(i)) for drugs typically lie in the same range as K(i) for natural ligands; in most instances (different proteins and docking conditions), vastatins are the strongest interactors, with atorvastatin ranking top in half of the cases. The affinity of some calycins for some of the vastatins is in the order of magnitude of the drug C(max) after systemic administration in humans. The possible biological implications of this feature are discussed in connection with drug delivery parameters (route of administration, binding to carrier proteins, distribution to, and accumulation in, human tissues). Public Library of Science 2015-07-13 /pmc/articles/PMC4500398/ /pubmed/26167932 http://dx.doi.org/10.1371/journal.pone.0132096 Text en © 2015 Beringhelli et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Beringhelli, Tiziana
Gianazza, Elisabetta
Maggioni, Daniela
Scanu, Sandra
Parravicini, Chiara
Sensi, Cristina
Monaco, Hugo L.
Eberini, Ivano
All-Purpose Containers? Lipid-Binding Protein – Drug Interactions
title All-Purpose Containers? Lipid-Binding Protein – Drug Interactions
title_full All-Purpose Containers? Lipid-Binding Protein – Drug Interactions
title_fullStr All-Purpose Containers? Lipid-Binding Protein – Drug Interactions
title_full_unstemmed All-Purpose Containers? Lipid-Binding Protein – Drug Interactions
title_short All-Purpose Containers? Lipid-Binding Protein – Drug Interactions
title_sort all-purpose containers? lipid-binding protein – drug interactions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500398/
https://www.ncbi.nlm.nih.gov/pubmed/26167932
http://dx.doi.org/10.1371/journal.pone.0132096
work_keys_str_mv AT beringhellitiziana allpurposecontainerslipidbindingproteindruginteractions
AT gianazzaelisabetta allpurposecontainerslipidbindingproteindruginteractions
AT maggionidaniela allpurposecontainerslipidbindingproteindruginteractions
AT scanusandra allpurposecontainerslipidbindingproteindruginteractions
AT parravicinichiara allpurposecontainerslipidbindingproteindruginteractions
AT sensicristina allpurposecontainerslipidbindingproteindruginteractions
AT monacohugol allpurposecontainerslipidbindingproteindruginteractions
AT eberiniivano allpurposecontainerslipidbindingproteindruginteractions